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Abstract
Objective: Several mechanisms of disease have been
implicated in the pathophysiology of small-for-gestation-
al-age (SGA) including an anti-angiogenic state, and an
exaggerated intravascular pro-inflammatory response.
Adiponectin plays a role in a wide range of biological
activities including those that have been implicated in the
pathophysiology SGA. Thus, the aim of this study was to
determine if third trimester adiponectin concentrations
differed between women with normal weight infants and
those with an SGA neonate.
Study design: This cross-sectional study included
women with: 1) a normal pregnancy (ns234); and 2) an
SGA neonate (ns78). SGA was defined as a birth weight
below the 10th percentile for gestational age at birth. The
study population was further stratified by first trimester
body mass index (BMI) (normal weight -25 kg/m2 vs.
overweight/obese G25 kg/m2). Maternal serum adipo-
nectin multimers wtotal, high-molecular-weight (HMW),
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medium-molecular-weight (MMW) and low-molecular-
weight (LMW)x concentrations were determined by
ELISA. Non-parametric statistics were used for analyses.
Results: 1) The median maternal serum concentrations
of total, HMW and MMW adiponectin were significantly
lower in patients with an SGA neonate than in those with
normal pregnancies; 2) patients with an SGA neonate
had a significantly lower median HMW/total adiponectin
ratio and higher median MMW/total adiponectin and
LMW/total adiponectin ratios than those with a normal
pregnancy; 3) among patients with an SGA neonate,
neither maternal serum concentrations of adiponectin
multimers, nor their relative distribution differ between
normal weight and overweight/obese patients.
Conclusion: 1) Pregnancies complicated by an SGA
neonate are characterized by a alterations in the maternal
serum adiponectin multimers concentrations and their
relative abundance; 2) the findings reported herein sug-
gest that maternal adipose tissue may play a role, in the
pathogenesis of SGA.
Keywords: Adipokines; adipose tissue; body mass
index (BMI); fetal growth; high-molecular-weight (HMW)
adiponectin; low-molecular-weight (LMW) adiponectin;
medium-molecular-weight (MMW) adiponectin; obesity;
overweight; pregnancy; small-for-gestational-age (SGA).
Introduction
Small-for-gestational-age (SGA) neonate, one of the
‘‘great obstetrical syndromes’’ w109, 110x, is usually
defined as a birth weight below the 10th percentile for
gestational age at birth according to the birth weight dis-
tribution of a particular population w124x. In accordance
with its syndromic nature, several mechanisms of dis-
ease have been implicated in the pathophysiology of this
complication including: endothelial cell dysfunction w17x,
an anti-angiogenic state w21, 22, 34, 42, 111, 118, 139x,
failure of physiologic transformation of the spiral arteries
w18, 39x, and an increased maternal intravascular pro-
inflammatory response w52, 66, 120, 125, 132x. Interest-
ingly, maternal overweight/obesity, has a protective effect
for the development of SGA fetuses w7, 19, 27, 33, 123,
145x.
Adipose tissue, once considered a passive depot for
energy storage, is now recognized as a potent endocrine
organ w134x. Adipocytes, and other cellular components
of adipose tissue, have a high capacity to produce and
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secrete adipokines. Recently, adipokines have been
implicated in the metabolic adaptation of normal gesta-
tion w20, 36, 73, 75, 77, 78, 80, 82, 84, 90, 92, 117, 130x,
as well as in complications of pregnancy such as pre-
eclampsia w29, 31, 46, 47, 54, 70, 85, 88, 91, 107, 120,
140x, gestational diabetes mellitus (GDM) w10, 23, 43, 56,
59, 60, 63, 68, 76, 108, 133, 149, 150x, intra-amniotic
infection/inflammation w65, 83, 141x, and abnormal fetal
growth w24, 35, 50, 53, 62, 67, 69, 79, 81, 95, 105, 136,
143x.
Much attention has been focused on the biological
actions of adiponectin, the adipokine w48, 71, 86, 119x
that circulates at highest concentrations in humans w5x.
Unlike other adipokines, circulating concentrations of this
adiponectin are lower in obese than in non-obese sub-
jects w8, 48x, suggesting a negative feedback on its pro-
duction or secretion by the adipose tissue. In addition to
its insulin sensitizing w12, 28, 72, 151x, anti-atherogenic
w26, 38, 64, 94, 98x, anti-inflammatory w25, 122, 127x, and
angiogenic w16, 100, 126x properties, adiponectin has
been consistently shown to have protective effects on
vasculature w74, 93, 96–98, 101x. Of note, several of the
abovementioned conditions in which adiponectin has
been implicated (e.g., angiogenesis, hypertension, ath-
erosclerosis and inflammation) are known risk factors for
the development of an SGA neonate.
Adiponectin circulates in human plasma in distinct
forms: 1) low-molecular-weight (LMW) trimers; 2)
medium-molecular-weight (MMW) hexamers; and 3)
high-molecular-weight (HMW) oligomers (12–18 subu-
nits) w9, 103, 104, 137, 138, 144x. A growing body of
evidence suggests that the physiological activity of adi-
ponectin is determined not only by the absolute concen-
trations of its multimeric complexes but, to a large extent,
by the relative distribution of these isoforms w61, 103,
104, 135, 138, 144x. Thus, a comprehensive evaluation
of its isoforms is essential to elucidate its role.
To date, no study has evaluated maternal circulating
concentrations of adiponectin multimers in patients with
an SGA neonate. Thus, the aim of this study was to
determine if third trimester adiponectin concentrations
differed between women with normal weight infants and
those with SGA neonate.
Materials and methods
Study groups and inclusion criteria
A cross-sectional study was conducted including patients in the
following groups: 1) women with a normal pregnancy (ns234);
and 2) patients with an SGA neonate (ns78). The study popu-
lation was further stratified by first trimester body mass index
(BMI: normal weight 18.5–24.9 kg/m2 vs. overweight/obese
G25 kg/m2).
Samples and data were retrieved from our bank of biological
samples and clinical databases. Many of these samples have
previously been employed to study the biology of inflammation,
hemostasis, angiogenesis regulation, and growth factor concen-
trations in normal pregnant women and those with pregnancy
complications.
Written informed consent was obtained from all participants
after approval by the Institutional Review Boards of the Sotero
del Rio Hospital (Chile), Wayne State University (Detroit, MI,
USA) and the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (NICHD; Bethesda,
MD, USA).
Clinical definitions
The inclusion criteria for women with a normal pregnancy were:
singleton gestation, no prior diabetes mellitus, no maternal or
fetal complications during pregnancy, normal plasma glucose
concentrations in the first trimester, normal oral glucose chal-
lenge test w1x, and delivery at term of a healthy neonate with a
birth weight above the 10th percentile for gestational age w6, 41x.
The diagnosis of SGA was based on ultrasonographic estimated
fetal weight and confirmed by a birth weight below the 10th
percentile for gestational age w6, 41x.
The BMI was calculated according to the formula: weight (kg)/
height (m2). Normal weight women were defined as those with
a BMI of 18.5–24.9 kg/m2 according to the definition of the
World Health Organization (WHO) w2x. Pregnant women were
classified by their first trimester BMI into two groups: normal
weight and overweight/obese (BMIG25 kg/m2).
Sample collection and quantitative determination
of maternal serum adiponectin multimers
Maternal blood samples were collected with a vacutainer into
tubes. Samples were centrifuged and the sera were stored at
–808C until analysis. Sensitive enzyme-linked immunoassays
were used to determine the concentrations of adiponectin
multimeric forms in maternal serum. Immunoassays kits were
purchased from ALPCO Diagnostics (47-ADPHU-E01, Salem,
NH, USA). The assays were run according to the manufacturer’s
recommendations. Maternal serum plasma samples that treated
with SDS-containing acid buffer to convert multimeric adiponec-
tin to a dimmer form were assayed to determine total adiponec-
tin concentrations. To detect HMW adiponectin, serum samples
were pretreated with a specific protease that selectively digested
MMW and LMW adiponectin and then treated with the SDS-
buffer that also stopped the digestion reaction. We were also
able to determine the combined HMW and MMW adiponectin
concentrations by pretreating the samples with a protease that
specifically digested LMW adiponectin. Briefly, recombinant
adiponectin (standards) and SDS-buffer-treated or protease-
pretreated maternal serum samples were incubated in duplicate
wells of the micro titer plates, which had been pre-coated with
a monoclonal antibody specific for adiponectin. During this incu-
bation any adiponectin present in the standards and SDS-buffer-
treated or protease-pretreated maternal serum samples was
bound by the immobilized antibodies. After repeated washing
and aspiration to remove all unbound substances, an enzyme-
linked polyclonal antibody specific for adiponectin was added
to the wells. Unbound materials were removed with repeated
washing and a substrate solution was added to the wells and
color developed in proportion to the amount of adiponectin
bound in the initial step. The color development was stopped
with the addition of an acid solution and the intensity of
color was read using a programmable spectrophotometer
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Table 2 Clinical and demographic characteristics of the study population according to body mass index.
Normal pregnancy P-value SGA P-value
Normal weight Overweight/obese Normal weight Overweight/obese
(ns118) (ns116) (ns35) (ns43)
Maternal age (years) 26.5 (21.0–31.0) 29.0 (24.0–34.0) -0.01 21.0 (18.2–29.7) 24.0 (20.0–32.0) NS
Parity 1 (0–2) 1 (1–2) 0.7 2 (1–3) 2 (1–3) 0.6
First trimester BMI (kg/m2) 22.7 (21.4–23.8) 27.3 (25.9–30.3) -0.01 22.1 (20.2–23.5) 30.6 (28.6–32.2) -0.01
Gestational age at blood 33.7 (31.2–40.0) 31.5 (27.3–33.8) 0.2 33.8 (28.0–37.5) 35.0 (27.0–38.6) 0.8
sampling (weeks)
Gestational age at delivery 40.0 (39.1–40.2) 39.8 (38.8–40.5) 0.9 36.0 (32.7–39.0) 38.6 (37.3–40.0) 0.3
(weeks)
Birth weight (g) 3420 (3205–3690) 3505 (3245–3735) 0.3 2422 (1813–2643) 2455 (2245–2650) 0.4
Values are expressed as median (interquartile range).
SGAssmall for gestational age, BMIsbody mass index.
Table 1 Clinical and demographic characteristics of the study population.
Normal pregnancy SGA P-value
(ns234) (ns78)
Maternal age (years) 28.0 (22.0–32.0) 24.0 (19.0–31.8) 0.004
Parity 1 (0–2) 2 (1–3) 0.3
Ethnic origin
Hispanic 203 (87%) 62 (79%) 0.1
African American 20 (9) 10 (13%) 0.3
Caucasian 6 (3%) 4 (5%) 0.3
Others 5 (2%) 2 (3%) 0.8
Smoking 12 (5%) 8 (10%) 0.1
First trimester BMI (kg/m2) 24.9 (22.8–27.3) 25.9 (22.6–30.9) 0.1
Gestational age at blood sampling (weeks) 32.7 (28.7–39.3) 34.5 (27.8–38.5) 0.3
Gestational age at delivery (weeks) 39.9 (39.0–40.4) 38.5 (37.2–39.5) 0.08
Birth weight (g) 3470 (3220–3700) 2452 (2140–2651) -0.001
Values are expressed as median (interquartile range) or numbers (percents).
SGAssmall for gestational age, BMIsbody mass index.
(Spectra-Max M2, Molecular Devices, Sunnyvale, CA, USA). The
concentration of adiponectin in SDS-buffer-treated or protease-
pretreated maternal serum samples was determined by
interpolation from individual standard curves composed of
human adiponectin. Total, HMW, and HMW-MMW adiponectin
concentrations were derived directly from the assay plates.
MMW adiponectin concentrations were obtained by subtracting
HMW adiponectin value from the combined HMW-MMW value.
Finally, the LMW adiponectin value was computed by subtract-
ing HMW and MMW adiponectin values from the total adipo-
nectin values. The calculated inter- and intra-assay coefficients
of variation for adiponectin multimer immunoassays in our lab-
oratory were 2.2% and 4.2%, respectively. The sensitivity was
calculated to be 0.04 ng/mL.
Statistical analysis
Normality of the data was tested using the Kolmogorov-Smirnov
test. Since serum multimeric adiponectin isoforms concentra-
tions were not normally distributed, Mann-Whitney U-tests were
used for comparisons of continuous variables. Kruskal-Wallis
test was used for the comparison between normal weight and
overweight/obese pregnant women with and without SGA. Com-
parison of proportions was performed with x2-tests. Multiple
linear regression analysis was performed to determine which
factors were significantly and independently associated with
maternal serum adiponectin isoforms concentrations as well as
their relative distribution. Due to skewed distribution of the data,
logarithmic (log) transformation was employed in the latter anal-
ysis. The following parameters were included in the model:
maternal age, maternal first trimester BMI (as a continuous var-
iable), gestational age at blood sampling, gestational age at
delivery, ethnic origin and the presence of SGA. A P-0.05 was
considered statistically significant. Analysis was performed with
SPSS, version 14 (SPSS Inc., Chicago, IL, USA).
Results
The demographic and clinical characteristics of women
with a normal pregnancy and those with an SGA neonate
are displayed in Table 1. Women with a normal pregnancy
had a higher median maternal age. There were no sig-
nificant differences in parity, gestational age at blood
sampling, gestational age at delivery and first trimester
BMI between patients with a normal pregnancy and
those with an SGA neonate (Table 1). Table 2 displays
the demographic and clinical characteristics of the study
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Figure 1 Comparison of the median serum total, HMW, MMW
and LMW adiponectin concentrations between women with nor-
mal pregnancies and those with an SGA neonate.
The median maternal serum concentrations of total, HMW and
MMW adiponectin were lower in patients with an SGA neonate
than that of those with a normal pregnancy. The median mater-
nal serum concentration of LMW adiponectin did not differ sig-
nificantly between patients with SGA and those with a normal
pregnancy.
Figure 2 Comparison of HMW/total adiponectin MMW/total
adiponectin and LMW/total adiponectin ratio between women
with normal pregnancies and those with an SGA neonate.
The median maternal HMW/total adiponectin ratio was lower in
patients with an SGA neonate than that of those with a normal
pregnancy. In contrast, patients with an SGA neonate had higher
median MMW/total adiponectin and LMW/total adiponectin
ratios than that of those with a normal pregnancy.
population according to BMI. Among women with a nor-
mal pregnancy, those with normal weight were younger
than overweight/obese patients. There were no signifi-
cant differences in parity, gestational age at blood
sampling, gestational age at delivery and neonatal birth
weight between normal weight and overweight/obese
women in both groups (Table 2).
Adiponectin multimers concentrations and their
relative distribution in SGA vs. normal pregnancy
The median maternal serum concentration of total adi-
ponectin was lower in patients with an SGA neonate than
that of women with a normal pregnancy wmedian:
3961 ng/mL, interquartile range (IQR) 3075–4958 vs.
6070 ng/mL, IQR 4640–8240; P-0.001, Figure 1x. Sim-
ilarly, patients with an SGA neonate had lower median
serum concentrations of HMW (1575 ng/mL, IQR
973–2600 vs. 3312 ng/mL, IQR 2236–4773; P-0.001,
Figure 1) and MMW adiponectin (1062 ng/mL, IQR
775–1361 vs. 1355 ng/mL, IQR 913–1804; P-0.001,
Figure 1) than women with a normal pregnancy. The
median maternal serum concentration of LMW adiponec-
tin did not differ significantly between patients with an
SGA neonate and women with a normal pregnancy
(1120 ng/mL, IQR 811–1493 vs. 1272 ng/mL, IQR
870–1722 respectively; Ps0.06, Figure 1).
The median maternal HMW/total adiponectin ratio was
lower in patients with an SGA neonate than in those with
a normal pregnancy (0.42, IQR 0.33–0.54 vs. 0.55, IQR
0.47–0.62; P-0.001, Figure 2). In contrast, patients with
an SGA neonate had higher median MMW/total adipo-
nectin (0.27, IQR 0.20–0.35 vs. 0.22, IQR 0.16–0.28;
P-0.001, Figure 2) and LMW/total adiponectin ratios
(0.28, IQR 0.21–0.37 vs. 0.21, IQR 0.15–0.28; P-0.001,
Figure 2) than women with a normal pregnancy.
Adiponectin multimers concentrations and their
relative distribution in normal weight pregnant
women: normal pregnancy vs. SGA
Among pregnant women with a normal weight, patients
with an SGA neonate had lower median serum concen-
trations of total adiponectin (3993 ng/mL, IQR
2869–5515 vs. 6859 ng/mL, IQR 4982–8695; P-0.001,
Figure 3A), HMW adiponectin (1717 ng/mL, IQR 878–
2609 vs. 3910 ng/mL, IQR 2467–5134; P-0.001, Figure
3B) and MMW adiponectin (1025 ng/mL, IQR 775–1376
vs. 1411 ng/mL, IQR 961–1911; Ps0.006, Figure 3C)
than women with a normal pregnancy. There was no sig-
nificant difference in the median maternal serum concen-
trations of LMW adiponectin between patients with an
SGA neonate and those with a normal pregnancy
(1145 ng/mL, IQR 788–1490 vs. 1295 ng/mL, IQR
915–1731 respectively; Ps0.1, Figure 3D).
Among normal weight women, patients with an SGA
neonate had a lower median HMW/total adiponectin ratio
than those with a normal pregnancy (0.45, IQR 0.33–0.55
vs. 0.56, IQR 0.49–0.63; P-0.001, Figure 4A). In con-
trast, the median MMW/total adiponectin (0.26, IQR
0.22–0.33 vs. 0.23, IQR 0.15–0.29; Ps0.007, Figure 4B)
and LMW/total adiponectin ratios (0.27, IQR 0.21–0.36
vs. 0.21, IQR 0.15–0.27; Ps0.001, Figure 4C) were
higher in patients with an SGA neonate than in those with
a normal pregnancy.
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Figure 3 Maternal serum total adiponectin (A), HMW adiponectin (B), MMW adiponectin (C) and LMW adiponectin (D) concentrations
in women with normal pregnancies and patients with an SGA neonate according to first trimester BMI (normal weight vs. overweight/
obese).
Among patients with an SGA neonate, normal weight pregnant women and those with overweight/obesity did not differ in the median
serum concentrations of total, HMW, MMW, and LMW adiponectin. Among patients with a normal weight, the median serum con-
centrations of total (A), HMW (B), and MMW (C) adiponectin were higher in pregnant women with a normal pregnancy than that of
those with an SGA neonate. Similar findings were found among patients with overweight/obesity. The median maternal serum con-
centration of LMW did not differ significantly between pregnant women with a normal pregnancy and those with an SGA neonate
regardless of maternal first trimester BMI category (D).
Adiponectin multimers concentrations and their
relative distribution in overweight/obese women:
normal pregnancy vs. SGA
Among pregnant women with overweight/obesity,
patients with an SGA neonate had lower median serum
concentrations of total adiponectin (3950 ng/mL, IQR
3086–4939 vs. 5434 ng/mL, IQR 4481–7732; P-0.001,
Figure 3A), HMW adiponectin (1526 ng/mL, IQR
1112–2624 vs. 3019 ng/mL, IQR 2133–4405; P-0.001,
Figure 3B) and MMW adiponectin (1080 ng/mL, IQR
695–1387 vs. 1344 ng/mL, IQR 898–1722; Ps0.01, Fig-
ure 3C) than women with a normal pregnancy. There was
no significant difference in the median maternal serum
concentrations of LMW adiponectin (1130 ng/mL, IQR
824–1622 vs. 1265 ng/mL, IQR 826–1719 respectively;
Ps0.4, Figure 3D) between patients with an SGA neo-
nate and those with a normal pregnancy.
Overweight/obese women with an SGA neonate had a
lower HMW/total adiponectin ratio than those with a
normal pregnancy (0.42, IQR 0.32–0.55 vs. 0.54, IQR
0.46–0.62; P-0.001, Figure 4A). In contrast, MMW/total
adiponectin (0.27, IQR 0.19–0.36 vs. 0.22, IQR
0.18–0.28; Ps0.02, Figure 4B) and LMW/total adiponec-
tin (0.28, IQR 0.20–0.39 vs. 0.22, IQR 0.15–0.28;
P-0.001, Figure 4C) ratios were higher in overweight/
obese pregnant women with an SGA neonate than in
those with a normal pregnancy.
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.
Figure 4 Comparison of HMW/total adiponectin (A), MMW/
total adiponectin (B) and LMW/total adiponectin (C) ratios
between women with a normal pregnancy and those with an
SGA neonate according to first trimester BMI (normal weight vs.
overweight/obese).
Among pregnant women with an SGA neonate, normal weight
patients and those with overweight/obesity had comparable
median HMW/total adiponectin, MMW/total adiponectin and
LMW/total adiponectin ratios. Both normal weight and over-
weight/obese women with a normal pregnancy had a higher
HMW/total adiponectin ratio than that of those with an SGA neo-
nate (A). In contrast, MMW/total adiponectin (B) and LMW/total
adiponectin ratios (C) were lower in pregnant women with a nor-
mal pregnancy than that of those with an SGA neonate, regard-
less of first trimester maternal BMI category.
Adiponectin multimers concentrations and their
relative distribution in women with an SGA neonate:
normal weight vs. overweight/obesity
Among patients with an SGA neonate, normal weight
pregnant women and those with overweight/obesity did
not differ significantly in the median serum concentra-
tions of total adiponectin (Ps0.98, Figure 3A), HMW adi-
ponectin (Ps0.7, Figure 3B), MMW adiponectin (Ps0.9,
Figure 3C) and LMW adiponectin (Ps0.7, Figure 3D).
Similarly, patients with an SGA neonate with normal
weight and those with overweight/obesity had compa-
rable median HMW/total adiponectin (Ps0.4, Figure 4A),
MMW/total adiponectin (Ps0.8, Figure 4B), and LMW/
total adiponectin (Ps0.8, Figure 4C) ratios.
Linear regression analysis was used to examine the
contribution of the presence of SGA on the serum con-
centration of adiponectin isoforms, while adjusting for
maternal age, gestational age at blood sampling, and
gestational age at delivery and ethnic origin. The final
regression model suggested that the presence of SGA
and first trimester BMI were independently associated
with low maternal serum concentrations of total adipo-
nectin (P-0.001 and Ps0.01, respectively), and HMW
adiponectin (P-0.001 and Ps0.002, respectively). In
addition, only the presence of SGA was independently
associated with low maternal serum concentrations of
MMW adiponectin (Ps0.04), and HMW/total adiponectin
ratio (P-0.001) as well as with high MMW/total adipo-
nectin (Ps0.001) and LMW/total adiponectin ratios
(P-0.001).
Discussion
Principal findings of the study
1) The median maternal serum concentrations of total,
HMW and MMW adiponectin were significantly lower in
patients with an SGA neonate than that of those with
normal pregnancies; 2) patients with an SGA neonate
had a significantly lower median HMW/total adiponectin
ratio and higher median MMW/total adiponectin and
LMW/total adiponectin ratios than those with a normal
pregnancy; 3) among patients with an SGA neonate,
neither maternal serum concentrations of adiponectin
multimers, nor their relative distribution differed between
normal weight and overweight/obese patients; and 4) the
presence of SGA was independently associated with a
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low maternal serum total, HMW, and MMW adiponectin
concentration, as well as with low HMW/total adiponectin
ratio and high MMW/total adiponectin and LMW/total
adiponectin ratios.
What is the rationale to assess maternal circulating
adiponectin in patients with SGA fetuses?
The rationale to determine the association between
maternal circulating adiponectin concentrations and fetal
growth hinges on the following findings: 1) adiponectin
is an important mediator of several biological processes
that have been implicated in the pathophysiology of
SGA. Adiponectin has insulin sensitizing w12, 28x,
anti-atherogenic w26, 38, 64, 94x, anti-inflammatory w25,
51, 114x, and angiogenic w14, 16, 100x properties, as well
as vasculature protective effects w74, 93, 96–98, 101x.
This unique and diverse combination of biological activ-
ities made adiponectin an attractive candidate to account
for both physiologic adaptations and pathologic states.
Indeed, SGA has been associated with an anti-angioge-
nic state w15, 21, 22, 30, 34, 40, 42, 111, 118, 139, 142,
146x, an exaggerated intravascular pro-inflammatory
response w40, 52, 66, 115, 120, 125, 132x, and hyperten-
sion w128, 129x; and 2) a growing body of evidence
supports a role for adiponectin in complications of preg-
nancy, including those closely associated with SGA, such
as preeclampsia. Indeed, preeclampsia is associated
with altered maternal adiponectin concentrations w29, 32,
46, 47, 54, 70, 88, 91, 107, 131x and low circulating
maternal adiponectin concentrations have been reported
in GDM w10, 59, 108, 133, 150x; and overweight pregnant
patients w90x.
Modifications of maternal serum adiponectin
multimers – functional implications
A solid body of evidence suggests that the biological
effects of adiponectin are determined not only by the
absolute concentrations of adiponectin multimeric com-
plexes, but, to a large extent, by the relative distribution
of its isoforms w9, 13, 61, 103, 104, 135, 138, 144x. More-
over, each isoform has different biological effects. This
view is supported by the following findings: 1) in vitro,
HMW and MMW adiponectin have pro-inflammatory
effects such as induction of IL-6 secretion by human
monocytes and activation of nuclear factor (NF)-kB w4,
45, 112, 138x; 2) LMW adiponectin inhibits the release of
IL-6 w89, 121x, and increases the secretion of IL-10 w89x,
an anti-inflammatory cytokine; and 3) plasma HMW/total
adiponectin ratio has a better correlation with insulin
resistance indices than total adiponectin concentrations.
Collectively, these data suggest a structure-function rela-
tionship of adiponectin multimers. Importantly, the post-
translational modifications resulting in the various
adiponectin isoforms, are performed exclusively by adi-
pocytes w147, 148x. Indeed, none of the multimeric forms
interchange with each other after their secretion w103x.
Thus, the dysregulation of adiponectin multimers can be
viewed as an index for adipose tissue dysfunction.
Pregnancy complicated by an SGA neonate – a
state of adipose tissue dysregulation?
The present report is the first study explicitly designed to
compare maternal serum concentrations of adiponectin
multimers between normal pregnant women and those
who delivered an SGA neonate. The findings that the
median maternal serum concentrations of total, HMW
and MMW adiponectin are lower in patients with SGA
neonates than in those with a normal pregnancy are
novel. The lower total adiponectin concentrations in
patients with SGA neonates is the consequence of a sig-
nificant lowering in maternal serum HMW adiponectin
concentrations, as evidenced by the low HMW/total adi-
ponectin ratio, yet, high MMW/total and LMW/total adi-
ponectin ratios. The shift from the HMW adiponectin
isoform to MMW and LMW adiponectin multimers may
have functional implications since the metabolic effects
of adiponectin are primarily mediated by HMW
adiponectin.
The finding reported herein concerning the lower total
adiponectin in patients with SGA fetuses than in those
with a normal pregnancy is in agreement with the results
of Kyriakakou et al. w67x in which maternal serum con-
centrations of total adiponectin were lower in patients
with an intrauterine growth restricted (IUGR) neonate
(ns20) than in controls (ns20). Consistent with the latter
report, Ong et al. w95x reported a negative correlation
between neonatal birth weight and maternal total adi-
ponectin, HMW adiponectin and HMW/total adiponectin
ratio in 58 women with normal pregnancies and AGA
neonates. The results of the present study extend the
previous studies by demonstrating that the low maternal
serum total adiponectin concentration is the result of a
selective lowering in HMW adiponectin. Moreover, we
were able to show that low maternal serum adiponectin
concentrations are a feature of normal weight as well as
overweight/obese patients. Our findings are in contrast
with those of Verhaeghe et al. w143x, Fasshauer et al. w35x
and Savvidou et al. w118x who reported similar maternal
circulating total adiponectin concentrations in patients
with SGA neonates and those with a normal pregnancy.
Differences in study design, definition of SGA, and clini-
cal characteristics of the study population can explain
the disparity among studies. In particular, our study
included a large group of mothers with SGA fetuses, at
a wider range of gestational ages and a relatively higher
rate of overweight/obese patients.
Why do patients with SGA fetuses have low serum
concentrations of total and HMW adiponectin
concentrations?
The alteration in maternal serum adiponectin multimers
reported herein favors insulin resistance. In such obser-
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vational study, it is difficult to unravel a cause and effect
relationship between circulating maternal adiponectin
isoforms concentrations and the delivery of an SGA neo-
nate. However, it is tempting to postulate that these
changes are aimed at meeting the metabolic demands
of the small fetus. Indeed, it has been proposed that the
insulin-sensitizing properties of adiponectin are mediated
specifically by the HMW isoforms w11, 37, 44, 55, 61, 87,
104x.
An alternative explanation can be that the low adipo-
nectin concentrations are not an adaptive metabolic
response to a primary insult that resulted in an SGA
fetus, but rather a consequence of this primary insult.
Pregnancies complicated by an SGA neonate are asso-
ciated with an anti-angiogenic state and an intravascular
pro-inflammatory response. Since adiponectin has anti-
inflammatory and angiogenic properties, it is conceivable
that its low concentration is a reflection of these under-
lying mechanisms. Indeed, low circulating adiponectin
concentrations have been reported in other conditions
associated with pro-inflammatory state such as over-
weight/obesity w3, 8, 48, 58, 90x and systemic lupus
erythematosus w113, 116x, diseases characterized by
impairment in vasculature integrity such as atheroscle-
rosis w99, 106x and hypertension w51, 57, 101x, and those
with anti-angiogenic states such as preeclampsia w29,
31, 32, 49, 102x.
Adiponectin multimers in normal and overweight/
obese patients with SGA fetuses – evidence for
altered regulation of adiponectin multimers
In contrast to normal pregnancy w8, 48, 75, 90x, over-
weight/obese patients with SGA neonates did not have
lower serum concentrations of total adiponectin or its
multimers compared to normal weight patients with SGA.
Similarly, overweight/obese and normal weight patients
with SGA did not differ in the relative distribution of adi-
ponectin isoforms. These findings suggest a genuine
association between the presence of SGA and alterations
in maternal circulating adiponectin, regardless of the
presence of obesity. This is further supported by the fact
that the presence of SGA was independently associated
with a low maternal serum concentration of HMW adi-
ponectin, as well as with a low HMW/total adiponectin
ratio. Collectively, these findings suggest altered regula-
tion of maternal serum adiponectin multimeric complexes
in the presence of SGA.
In conclusion, the present study is the first to deter-
mine maternal serum adiponectin multimers concentra-
tions in patients with SGA neonates. The findings
reported herein suggest that maternal adipose tissue
plays an important and hitherto unrecognized role in the
pathogenesis of SGA. These observations lend support
to the hypothesis that adipokines play an important role
not only in the physiologic adaptation of human gestation
but also in complications of pregnancy. The implicit
promise of adipokines research during normal and
abnormal pregnancy is that lifestyle or pharmacologic
interventions may be helpful in the prevention and/or
treatment of pregnancy complications such as the deliv-
ery of an SGA neonate.
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